Generex Publishes Results From Pre-Clinical Studies On Immunotherapeutic Vaccine for HPV-Induced Cervical Cancer
The Antigen Express studies demonstrate that mice immunized with an Ii-Key/HPV16 E7 hybrid show increased killing of cells expressing an HPV-specific antigen, but not control cells lacking the antigen. Consistent with the predicted mechanism of action of the vaccine, HPV-specific activation of CD4+ T helper cells was observed in immunized mice. The first author of the study, Dr. Minzhen Xu, is Vice-President of Biology at Antigen Express.
The current studies demonstrate an additional application of the Ii-Key technology platform being developed at Antigen Express. Currently, another peptide designed with this technology is the subject of three clinical trials: a Phase II trial in breast cancer patients, a Phase I trial in prostate cancer patients, and a separate Phase I trial in breast or ovarian cancer patients wherein it is being tested in combination with another peptide vaccine. That immunotherapeutic vaccine, AE37, couples Ii-Key with a fragment of the HER2 protein, which is expressed in a variety of cancers and is associated with worse prognosis.
While prophylactic vaccines against HPV-induced cervical cancer are available, those vaccines do not benefit patients once cancer has arisen. The difference is that Ii-Key/HPV hybrid vaccines help to induce a cellular immune response, which is necessary for killing cancer cells.
Original publication: “Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers”; Vaccine July 2009, Volume 27, Issue 34
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.